Security Snapshot

BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (BBIO) Institutional Ownership

CUSIP: 10806X102

13F Institutional Holders and Ownership History from Q2 2019 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

357

Shares (Excl. Options)

149.85MFull value: 149,846,893 · shares · 30 Sep 2026

Price

$65.80

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.02%
Share change
+5,133,007
Value change
+$317,209,535
Number of holders
357
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
195,164,384
SEC-reported price per share
$70.73
Insider filing price
$70.73
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") is tracked under CUSIP 10806X102.
  • 357 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 475 to 357 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $14.43BFull value: $14,428,096,702 · USD · 30 Jun 2026
    to
    $9.9BFull value: $9,899,752,865 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 357 institutions filings for Q3 2026.

Open SEC evidence

Security key

10806X102

13F reference period

Q3 2026

13F holders

357

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
BBIO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FARALLON CAPITAL MANAGEMENT, L.L.C. 7.3% +36% $937,452,600 +$230,559,055 14,247,000 +33% Farallon Capital Management, L.L.C. 30 Sep 2026
JANUS HENDERSON GROUP PLC 6.8% +18% $977,092,024 +$161,518,142 13,179,013 +20% JANUS HENDERSON GROUP PLC 31 Mar 2026
Farallon Capital Partners, L.P. 5.2% $674,408,855 10,226,063 Dapice Joshua J. 22 May 2026
BlackRock, Inc. 5.1% +2.8% $650,908,471 +$10,426,931 9,892,226 +1.6% BlackRock, Inc. 30 Sep 2026
VIKING GLOBAL INVESTORS LP 5% -18% $729,325,450 -$152,700,218 9,792,219 -17% VIKING GLOBAL INVESTORS LP 09 Jul 2026
Kumar Neil 4.6% -16% $689,354,243 -$87,903,790 9,282,982 -11% NEIL KUMAR 31 Mar 2026
KKR Genetic Disorder L.P. 4.7% -33% $719,322,695 -$313,839,555 9,232,739 -30% KKR Group Partnership L.P. 13 Aug 2026
As of 30 Sep 2026, 357 institutional investors reported holding
149.85MFull value: 149,846,893 · shares · 30 Sep 2026
shares of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (BBIO). This represents 77% of the company’s total
195.16MFull value: 195,164,384 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
58%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Janus Henderson Group Ltd. 7.5% 14,555,010 0.41% $957,695,614
FARALLON CAPITAL MANAGEMENT, L.L.C. 7.3% 14,247,000 4.9% $937,452,600
VIKING GLOBAL INVESTORS LP 5% 9,792,219 2% $644,328,010
WELLINGTON MANAGEMENT GROUP LLP 4.8% 9,458,992 0.11% $622,401,674
Kohlberg Kravis Roberts & Co. L.P. 4.2% 8,260,971 11% $543,571,892
VANGUARD CAPITAL MANAGEMENT LLC 4.1% 7,914,105 0.01% $520,748,109
VANGUARD PORTFOLIO MANAGEMENT LLC 3.8% 7,485,198 0.02% $492,526,028
STATE STREET CORP 2.6% 4,977,159 0.01% $327,497,062
Invesco Ltd. 2.2% 4,316,893 0.02% $284,051,542
TWO SIGMA INVESTMENTS, LP 1.9% 3,660,083 0.17% $240,833,461
GEODE CAPITAL MANAGEMENT, LLC 1.7% 3,278,852 0.01% $215,806,087
Aisling Capital Management LP 1.6% 3,089,611 68% $203,296,404
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.6% 3,031,958 0.28% $199,502,836
Paradigm Biocapital Advisors LP 1.2% 2,347,850 3.1% $154,488,530
Polar Capital Holdings Plc 1.1% 2,150,729 0.4% $141,517,968
MANUFACTURERS LIFE INSURANCE COMPANY, THE 1% 1,950,745 0.1% $128,359,021
SC US (TTGP), LTD. 0.95% 1,860,364 0.48% $122,411,951
PRIMECAP MANAGEMENT CO/CA/ 0.87% 1,699,422 0.07% $111,821,968
Pictet Asset Management Holding SA 0.87% 1,690,829 0.11% $111,290,441
BANK OF AMERICA CORP /DE/ 0.73% 1,418,879 0.01% $93,362,236
FRONTIER CAPITAL MANAGEMENT CO LLC 0.71% 1,392,799 0.98% $91,646,164
GOLDMAN SACHS GROUP INC 0.71% 1,379,382 0.01% $90,763,331
Hood River Capital Management LLC 0.68% 1,324,297 0.74% $87,138,743
Laurion Capital Management LP 0.66% 1,288,169 6.4% $84,761,520
ALLIANCEBERNSTEIN L.P. 0.61% 1,197,257 0.02% $78,779,513

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
30
Headline period
Q3 2026
Rows shown
1-25 of 30
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 149,846,893 $9,899,752,865 +$317,209,535 $65.80 357
2026 Q2 193,824,337 $14,428,096,702 -$86,727,633 $74.48 475
2026 Q1 194,185,579 $14,422,832,660 +$364,041,432 $74.26 462
2025 Q4 188,214,200 $14,404,286,659 +$186,537,774 $76.49 429
2025 Q3 184,963,434 $9,606,937,258 -$158,160,333 $51.94 389
2025 Q2 188,818,044 $8,154,464,813 +$171,957,099 $43.18 357
2025 Q1 185,173,982 $6,405,659,483 +$325,204,372 $34.57 302
2024 Q4 176,645,317 $4,847,193,349 +$87,655,048 $27.44 260
2024 Q3 172,596,886 $4,393,814,683 -$68,086,150 $25.46 251
2024 Q2 174,953,530 $4,431,556,073 +$57,307,408 $25.33 249
2024 Q1 171,539,419 $5,303,582,949 +$162,256,099 $30.92 240
2023 Q4 165,715,337 $6,690,573,516 +$142,779,397 $40.37 246
2023 Q3 161,102,840 $4,243,730,776 +$304,390,990 $26.37 219
2023 Q2 149,815,028 $2,576,329,186 -$39,862,601 $17.20 196
2023 Q1 152,372,388 $2,526,139,807 +$155,256,748 $16.58 210
2022 Q4 144,623,389 $1,101,997,850 -$14,634,842 $7.62 175
2022 Q3 145,248,661 $1,443,911,522 +$48,733,339 $9.94 170
2022 Q2 140,449,294 $1,275,283,327 -$23,547,672 $9.08 153
2022 Q1 143,303,557 $1,454,787,082 -$23,988,513 $10.15 167
2021 Q4 141,976,495 $2,367,117,577 -$117,448,257 $16.68 181
2021 Q3 140,028,398 $6,563,888,337 -$165,004,819 $46.87 206
2021 Q2 142,676,491 $8,697,122,835 +$97,636,690 $60.96 197
2021 Q1 141,085,070 $8,688,930,801 +$1,238,074,220 $61.60 194
2020 Q4 121,079,579 $8,609,553,572 +$172,667,185 $71.11 160
2020 Q3 117,841,767 $4,393,419,330 +$21,644,575 $37.52 128
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .